DiaMedica Therapeutics

DiaMedica Therapeutics Inc.

14 Investors

Biopharmaceutical Development

MINNEAPOLIS, MN

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for diseases with significant unmet medical needs, primarily focusing on neurological and vascular conditions. Its lead candidate, DM199, is a synthetic form of the human KLK1 protein being investigated for acute ischemic stroke and preeclampsia.

Products & Team

DM199 (rinvecalinase alfa)

Recombinant Protein TherapeuticSeed

DM199 is DiaMedica's flagship product candidate, a synthetic (recombinant) version of the naturally occurring human tissue kallikrein-1 (KLK1) protein. This enzyme plays a vital role in regulating blood flow, inflammation, and oxidative stress. The drug is currently in Phase 2/3 clinical trials for the treatment of acute ischemic stroke (AIS), preeclampsia, and has also been studied for diabetic kidney disease.

Value Proposition

DM199 addresses the lack of effective or widely applicable therapies for serious conditions. For acute ischemic stroke, it targets patients who are not eligible for current treatments, and for preeclampsia, it represents a potential first-in-class pharmacological treatment where none are currently FDA-approved.

Pain Points

For stroke patients, the key problems are the narrow treatment window of existing therapies and the need for treatments that improve recovery. For pregnant individuals with preeclampsia, the primary pain point is the complete lack of FDA-approved pharmacological treatments to manage the condition and mitigate risks to both mother and fetus.

Aims to restore normal levels of the KLK1 protein to improve blood flow and reduce inflammation.Investigated for an extended treatment window of up to 24 hours post-symptom onset for AIS.Demonstrated a favorable safety profile in a preeclampsia trial, with data suggesting it does not cross the placental barrier.Has received orphan drug designation in the U.S. for a potential application.